KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Equity Ratio (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Equity Ratio for 15 consecutive years, with 0.77 as the latest value for Q2 2025.

  • On a quarterly basis, Equity Ratio rose 5.77% to 0.77 in Q2 2025 year-over-year; TTM through Jun 2025 was 0.77, a 5.77% increase, with the full-year FY2024 number at 0.76, up 4.97% from a year prior.
  • Equity Ratio was 0.77 for Q2 2025 at Supernus Pharmaceuticals, up from 0.77 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.77 in Q2 2025 to a low of 0.48 in Q4 2021.
  • A 5-year average of 0.62 and a median of 0.62 in 2023 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: fell 3.36% in 2022, then surged 43.3% in 2023.
  • Supernus Pharmaceuticals' Equity Ratio stood at 0.48 in 2021, then grew by 7.77% to 0.52 in 2022, then soared by 38.56% to 0.72 in 2023, then grew by 4.97% to 0.76 in 2024, then rose by 1.65% to 0.77 in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Equity Ratio are 0.77 (Q2 2025), 0.77 (Q1 2025), and 0.76 (Q4 2024).